If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 181 - 190 of 266
A Randomized, Open-Label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Objective
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)
Protocol No
JNJ-61186372COR3002-ORIGAMI-3
Categories
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Objective
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Protocol No
NRG-GI011
Categories
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects with Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
Objective
A Phase 1B Study of Neoadjuvant Xaluritamig Therapy in Patients with Newly Diagnosed Localized Intermediate or High Risk Prostate Cancer
Protocol No
AMGEN-AMG-509-20230237
Categories
A Phase 3, Randomized, Open-Label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination with Physician's Choice Chemotherapy Compared to Trastuzumab in Combination with Physician's Choice Chemotherapy for th
Objective
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Protocol No
JAZZ-JZP598-303-EMPOWHER
Categories
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Objective
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Protocol No
ECOG-EA3191
Categories
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination with Ruxolitinib in Participants with Newly Diagnosed Chronic Graft-Versus-Host Disease
Objective
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Protocol No
INCYTE-INCA-34176-254
Categories
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Periphera
Objective
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Protocol No
TSCAN-001
Categories
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive fo
Objective
A Phase1 Study of NT-112 in Patients with Advanced Solid Tumors Positive for KRAS G12D Mutation
Protocol No
NEOGENE-NT-112-301
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
FIH study of ISB-2001 in R/R multiple myeloma subjects
Protocol No
ICHNOS-ISB-2001-101
Categories